<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="rapid-communication"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Chem Res Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">Chem Res Toxicol</journal-id><journal-id journal-id-type="publisher-id">tx</journal-id><journal-id journal-id-type="coden">crtoec</journal-id><journal-title-group><journal-title>Chemical Research in Toxicology</journal-title></journal-title-group><issn pub-type="ppub">0893-228X</issn><issn pub-type="epub">1520-5010</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38055372</article-id><article-id pub-id-type="pmc">PMC10731652</article-id>
<article-id pub-id-type="doi">10.1021/acs.chemrestox.3c00253</article-id><article-categories><subj-group><subject>Communication</subject></subj-group></article-categories><title-group><article-title>Investigating
the Immune Basis of Green Tea Extract
Induced Liver Injury in Healthy Donors Expressing HLA-B*35:01</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3568-8928</contrib-id><name><surname>Line</surname><given-names>James</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-1" ref-type="notes">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Ali</surname><given-names>Serat-E</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes-1" ref-type="notes">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Grice</surname><given-names>Sophie</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Rao</surname><given-names>Tai</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath5"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4107-7832</contrib-id><name><surname>Naisbitt</surname><given-names>Dean J.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department
of Pharmacology and Therapeutics, <institution>University
of Liverpool</institution>, Sherrington Building, Ashton Street, Liverpool L69 3GE, <country>United
Kingdom</country></aff><aff id="aff2"><label>&#x02021;</label>Department
of Clinical Pharmacology, Xiangya Hospital, <institution>Central South University</institution>, Changsha 410008, <country>China</country></aff><aff id="aff3"><label>&#x000a7;</label>Hunan
Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, <institution>Central South University</institution>, Changsha 410008, <country>China</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Telephone: <phone>+44 151 7945346</phone>. E-mail: <email>dnes@liv.ac.uk</email>.</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><day>18</day><month>12</month><year>2023</year></pub-date><volume>36</volume><issue>12</issue><fpage>1872</fpage><lpage>1875</lpage><history><date date-type="received"><day>22</day><month>08</month><year>2023</year></date><date date-type="accepted"><day>01</day><month>12</month><year>2023</year></date><date date-type="rev-recd"><day>27</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx3c00253_0004" id="ab-tgr1"/></p><p>Epigallocatechin-3-<italic>O</italic>-gallate (EGCG) is the major
component of green tea extract, commonly found in dietary supplements,
and has been associated with immune-mediated liver injury. The purpose
of this study was to investigate the immunogenicity of EGCG in healthy
donors expressing HLA-B*35:01, and characterize EGCG responsive T-cell
clones. We have shown that EGCG can prime peripheral blood mononuclear
cells and T-cells from donors with and without the HLA-B*35:01 allele.
T-cell clones were CD4<sup>+ve</sup> and capable of secreting Th1,
Th2, and cytolytic molecules. These data demonstrate that EGCG can
activate T-cells <italic>in vitro</italic>, suggesting a significant
role in the pathogenesis of green tea extract induced liver injury.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution>Research Councils UK</institution><institution-id institution-id-type="doi">10.13039/501100000265</institution-id></institution-wrap></funding-source><award-id>MR/R009635/</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>tx3c00253</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>tx3c00253</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p>Herbal and
dietary supplements
(HDSs) have become a frequent component of daily life for millions
of people across the globe, with over 50% of the US population taking
at least one HDS per day.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> HDSs account
for 20% of drug-induced liver injury (DILI) in the US, with the increased
usage of HDSs over the last few decades correlating with an increase
in the proportion of DILI cases that are attributable to HDSs.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Green tea extract (GTE) is derived from the <italic>Camellia sinensis</italic> plant and is a common constituent of multi-ingredient
HDSs. Since 2006, GTE has been linked to over 50 cases of idiosyncratic
liver injury.<sup><xref ref-type="bibr" rid="ref3">3</xref>&#x02212;<xref ref-type="bibr" rid="ref6">6</xref></sup> GTE-DILI is characterized by hepatocellular liver damage (with increases
in serum transaminases) and is fatal in around 9% of cases.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Features of the reactions including a delayed
onset, resolution of clinical symptoms following cessation of GTE
intake, and rapid reoccurrence of symptoms upon rechallenge suggests
they may be immune mediated.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup></p><p>There
are multiple major catechins present in GTE, with (&#x02212;)
epigallocatechin-3-<italic>O</italic>-gallate (EGCG) being the most
abundant, making up between 5 and 12% of the bioavailable catechins.<sup><xref ref-type="bibr" rid="ref7">7</xref>,<xref ref-type="bibr" rid="ref8">8</xref></sup> EGCG is among several herbal derived flavonoid compounds that have
a strong association with the expression of HLA-B*35:01 and hepatocellular
or cholestatic liver injury. 72% of confirmed GTE-DILI patients express
the risk allele, which is otherwise present in the population at between
5 and 15%.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup></p><p>In vivo studies have
been conducted in programmed cell death protein
1 (PD-1)<sup>(&#x02212;/&#x02212;)</sup> murine models, which demonstrated
that at doses considered safe, GTE can drive increased ALT levels
and increase the population of cytotoxic T-cells present in the liver.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup></p><p>The aim of this study was to investigate
the immunogenicity of
EGCG using <italic>in vitro</italic> techniques, utilizing peripheral
blood mononuclear cells (PBMCs) and T-cells from healthy donors, in
addition to interrogating the allele restriction of any responses
observed.</p><p>PBMCs from HLA-B*35:01 positive and negative healthy
donors were
cocultured with EGCG (25 &#x003bc;M) for 3 weeks and restimulated every
7 days with irradiated autologous PBMC, EGCG (25 &#x003bc;M), and IL-2
before being washed and rechallenged with various concentrations of
EGCG (1&#x02013;50 &#x003bc;M). Priming of PBMC to EGCG was identified
in 2 of 4 allele positive donors and 1 of 4 allele negative donors,
with statistically significant (<italic>p</italic> &#x0003c; 0.0001) proliferation
in response to EGCG treatment (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>A). Additionally, secretion of T<sub>h</sub>1, T<sub>h</sub>2, and cytolytic molecules (IFN-&#x003b3;, IL-5, IL-13, and
Granzyme B) was observed (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>(a) Priming of PBMC isolated from HLA-B*35:01 positive
(green)
and HLA-B*35:01 negative (red) healthy donors. EGCG (25 &#x003bc;M)
and PBMCs were cocultured for 3 weeks and restimulated every 7 days
with irradiated autologous PBMCs, EGCG (25 &#x003bc;M), and IL-2. Cells
were washed on day 21 and rechallenged with either EGCG or cell culture
medium for 48 h. (a) A proliferation reading was taken, through addition
of <sup>3</sup>H thymidine for the final 16 h. Statistical significance
was determined using a Mann&#x02013;Whitney test (**<italic>p</italic> &#x0003c; 0.01, ****<italic>p</italic> &#x0003c; 0.0001). (b) Cytokine secretion
was measured from assay supernatant pooled from each condition using
cytometric bead-based immunoassays (LEGENDplex, BioLegend Custom Human
11-plex panel) carried out per manufacturer&#x02019;s instructions
using a BD FACS Canto II.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx3c00253_0001" id="gr1" position="float"/></fig><p>Furthermore, T-cells isolated from random (non-HLA typed) healthy
donors were cocultured with autologous monocyte derived dendritic
cells (moDCs) and EGCG (25 &#x003bc;M) in the presence or absence of
anti-PD-1 or programmed cell death ligand 1 (PD-L1) blocking antibodies
(5 &#x003bc;g/mL). After 12 days, cells were washed and rechallenged
with EGCG (25 &#x003bc;M) and a proliferation reading was taken. Priming
of T-cells was enhanced in the presence of PD-1 and PD-L1 blockade,
with stimulation index (SI) figures of over 10 in conditions subject
to immune checkpoint blockade, compared to a maximum SI of 4 in unblocked
conditions (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>A,B). These data suggest that EGCG is immunogenic in nature and is
able to prime PBMCs and T-cells from allele positive and negative
healthy donors.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Priming of T-cells isolated from random healthy donors.
(a) T-cells
and monocyte derived dendritic cells (moDCs) were cocultured with
EGCG (25 &#x003bc;M) in the presence or absence of PD-1 and PD-L1 blocking
antibodies (5 &#x003bc;g/mL) for 12 days. After 12 days, cells were
washed and rechallenged with EGCG (25 &#x003bc;M) or cell culture medium
and a proliferation readout taken as previously described. (b) Visualization
of priming data demonstrating increased number of proliferative wells
on inclusion of PD-1 and PD-L1 blockade.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx3c00253_0002" id="gr2" position="float"/></fig><p>EGCG-specific T-cell clones (TCCs), generated by serial dilution,<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> were identified in 2 healthy donors positive
for HLA-B*35:01 expression (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A). Drug-reactive T-cells that proliferated in a dose-dependent
manner with EGCG were restricted to CD4<sup>+ve</sup> monoclonal populations
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B). Clones
were observed to secrete both Th<sub>1</sub> (IFN-&#x003b3;) and Th<sub>2</sub> (IL-5 and IL-13) cytokines. Most notably, secretion of Granzyme
B was detected in all TCC profiled, indicating involvement of cytotoxic
T-cell responses and potential for inducing liver injury (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>C).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>(a) Proliferation of
TCC generated from HLA-B*35:01 positive donors
(<italic>n</italic> = 2) following treatment with EGCG. TCCs were
rechallenged in the presence of APCs with EGCG or cell culture medium
for 48 h. Proliferation was measured as previously described. TCCs
with a stimulation index (SI) &#x0003e; 1.5 were deemed to be responsive.
(b) Dose-dependent proliferation of CD4<sup>+ve</sup> EGCG-specific
TCCs. Clones were incubated with various concentrations of EGCG in
the presence of APCs, and proliferation was measured as previously
described. Statistical significance was determined using a Kruskal&#x02013;Wallis
test (*<italic>p</italic> &#x0003c; 0.05). (c) Cytokine secretion of CD4<sup>+ve</sup> EGCG-specific TCCs. Clones were incubated with EGCG (50
&#x003bc;M) or cell culture medium for 48 h. Secretion of IFN-&#x003b3;,
IL-5, Granzyme B, IL-13, IL-17, IL-22, and Perforin was conducted
using an enzyme-linked immunospot (ELISpot) as per the manufacturer&#x02019;s
instructions (Mabtech, Sweden). (d) HLA restriction of EGCG-responsive
TCCs. Proliferation in response to EGCG (50 &#x003bc;M) following blockade
of HLA complexes by anti-HLA antibodies (10 &#x003bc;g/mL). A proliferation
readout was taken as described previously, and statistical significance
was determined using a 2-way ANOVA (****<italic>p</italic> &#x0003c; 0.0001).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tx3c00253_0003" id="gr3" position="float"/></fig><p>TCCs and autologous antigen presenting cells (APCs)
were treated
with EGCG in the presence or absence of anti-HLA blocking antibodies.
Proliferation of TCC was largely unaffected after HLA class I blockade
(HLA-A, HLA-B, and HLA-C). However, proliferation was found to be
inhibited in the presence of MHC class II blocking antibodies, indicating
that T-cell responses to EGCG are driven primarily by MHC class II
complexes (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>D). These data suggest that EGCG is able to activate CD4<sup>+ve</sup> TCC but do not rule out interactions with CD8<sup>+ve</sup> TCCs,
which may be responsible for the small reduction in proliferation
seen under MHC Class I blockade, suggesting that MHC Class I may have
some role in antigen presentation.</p><p>In conclusion, EGCG is demonstrated
to be inherently immunogenic,
capable of priming PBMCs and T-cells from healthy donors that are
positive and negative for the HLA-B*35:01 risk allele. Priming of
immune cells demonstrates a dose-dependent trend and is enhanced through
the addition of PD-1 and PD-L1 immune checkpoint blockade as demonstrated
by <italic>in vivo</italic> research by Cho et al. in 2021. EGCG-responsive
T-cells displaying a CD4<sup>+ve</sup> phenotype were generated from
2-drug na&#x000ef;ve healthy donors expressing the HLA-B*35:01
risk allele, associated with GTE-DILI. We have been able to identify
TCCs that proliferate and secrete both cytotoxic and inflammatory
cytokines such as IFN-&#x003b3; and Granzyme B, suggesting these CD4<sup>+ve</sup> T-cells may be responsible for the tissue damage seen.
T-cell responses observed in this study were largely driven through
MHC Class II (HLA-DR) interactions and not reliant upon expression
of the MHC Class I allele association to respond. These data however
do not exclude the possibility that CD8<sup>+ve</sup> TCCs may be
present in small numbers or in the tissue resident compartment in
patients and contribute to the clinical phenotype seen.</p><p>Further
investigations into the allele restriction of EGCG responses
are warranted, with cloning experiments focusing on individuals negative
for HLA-B*35:01 expression needed to identify whether the generation
of TCCs is possible in donors not expressing the risk allele. Additional
functional T-cell analysis will be required to determine the mechanism
by which EGCG is presented to T-cells in a processing-dependent or
-independent manner. Further studies are ongoing to identify CD8<sup>+ve</sup> TCCs from healthy donors, and work is ongoing to recruit
GTE-DILI patients to the study.</p></body><back><notes notes-type="" id="notes-1"><title>Author Contributions</title><p><sup>&#x022a5;</sup> J.L. and
S.-E.A. contributed equally.</p></notes><notes notes-type="funding-statement" id="notes-2"><p>J.L. is a Ph.D.
student funded by the British Pharmacological Society&#x02019;s AJ
Clark Studentship; S.-E.A. is a Ph.D. graduate funded by the MRC DiMeN
Doctoral Training Partnership; S.G. is a Ph.D. student funded by the
MRC ITTP Studentship; T.R. is a Post-Doctoral Fellow funded by the
China Scholarship Council. This work was funded by a grant from the
MRC (grant number MR/R009635/1).</p></notes><ack><title>Acknowledgments</title><p>The authors would
like to thank both the volunteers who participated
in the project and the clinical research nurses involved in collecting
blood samples.</p></ack><glossary id="dl1"><def-list><title>Abbreviations</title><def-item><term>APCs</term><def><p>antigen presenting cells</p></def></def-item><def-item><term>DILI</term><def><p>drug-induced liver injury</p></def></def-item><def-item><term>HDS</term><def><p>herbal and dietary
supplement</p></def></def-item><def-item><term>HLA</term><def><p>human
leukocyte antigen</p></def></def-item><def-item><term>PBMCs</term><def><p>peripheral blood mononuclear cells</p></def></def-item><def-item><term>SI</term><def><p>stimulation index</p></def></def-item><def-item><term>TCC</term><def><p>T-cell clone</p></def></def-item><def-item><term>GTE</term><def><p>green tea extract</p></def></def-item><def-item><term>EGCG</term><def><p>epigallocatechin-3-<italic>O</italic>-gallate</p></def></def-item><def-item><term>MHC</term><def><p>major histocompatibility
complex</p></def></def-item><def-item><term>PD-1</term><def><p>programmed
cell death protein 1</p></def></def-item><def-item><term>PD-L1</term><def><p>programmed cell death ligand 1</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Bailey</surname><given-names>R. L.</given-names></name>; <name><surname>Gahche</surname><given-names>J. J.</given-names></name>; <name><surname>Lentino</surname><given-names>C. V.</given-names></name>; <name><surname>Dwyer</surname><given-names>J. T.</given-names></name>; <name><surname>Engel</surname><given-names>J. S.</given-names></name>; <name><surname>Thomas</surname><given-names>P. R.</given-names></name>; <name><surname>Betz</surname><given-names>J. M.</given-names></name>; <name><surname>Sempos</surname><given-names>C. T.</given-names></name>; <name><surname>Picciano</surname><given-names>M. F.</given-names></name>
<article-title>Dietary
supplement use in the United States, 2003&#x02013;2006</article-title>. <source>J. Nutr.</source>
<year>2011</year>, <volume>141</volume>, <fpage>261</fpage>&#x02013;<lpage>266</lpage>. <pub-id pub-id-type="doi">10.3945/jn.110.133025</pub-id>.<pub-id pub-id-type="pmid">21178089</pub-id>
</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Navarro</surname><given-names>V. J.</given-names></name>; <name><surname>Barnhart</surname><given-names>H.</given-names></name>; <name><surname>Bonkovsky</surname><given-names>H. L.</given-names></name>; <name><surname>Davern</surname><given-names>T.</given-names></name>; <name><surname>Fontana</surname><given-names>R. J.</given-names></name>; <name><surname>Grant</surname><given-names>L.</given-names></name>; <name><surname>Reddy</surname><given-names>K. R.</given-names></name>; <name><surname>Seeff</surname><given-names>L. B.</given-names></name>; <name><surname>Serrano</surname><given-names>J.</given-names></name>; <name><surname>Sherker</surname><given-names>A. H.</given-names></name>; <name><surname>Stolz</surname><given-names>A.</given-names></name>; <name><surname>Talwalkar</surname><given-names>J.</given-names></name>; <name><surname>Vega</surname><given-names>M.</given-names></name>; <name><surname>Vuppalanchi</surname><given-names>R.</given-names></name>
<article-title>Liver injury from herbals and dietary
supplements in the U.S. Drug-Induced Liver Injury Network</article-title>. <source>Hepatology</source>
<year>2014</year>, <volume>60</volume>, <fpage>1399</fpage>&#x02013;<lpage>1408</lpage>. <pub-id pub-id-type="doi">10.1002/hep.27317</pub-id>.<pub-id pub-id-type="pmid">25043597</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Bjornsson</surname><given-names>E.</given-names></name>; <name><surname>Olsson</surname><given-names>R.</given-names></name>
<article-title>Serious adverse liver reactions associated with herbal
weight-loss supplements</article-title>. <source>J. Hepatol</source>
<year>2007</year>, <volume>47</volume>, <fpage>295</fpage>&#x02013;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2007.05.010</pub-id>.<pub-id pub-id-type="pmid">17562348</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Hoofnagle</surname><given-names>J. H.</given-names></name>; <name><surname>Bonkovsky</surname><given-names>H. L.</given-names></name>; <name><surname>Phillips</surname><given-names>E. J.</given-names></name>; <name><surname>Li</surname><given-names>Y. J.</given-names></name>; <name><surname>Ahmad</surname><given-names>J.</given-names></name>; <name><surname>Barnhart</surname><given-names>H.</given-names></name>; <name><surname>Durazo</surname><given-names>F.</given-names></name>; <name><surname>Fontana</surname><given-names>R. J.</given-names></name>; <name><surname>Gu</surname><given-names>J.</given-names></name>; <name><surname>Khan</surname><given-names>I.</given-names></name>; <name><surname>Kleiner</surname><given-names>D. E.</given-names></name>; <name><surname>Koh</surname><given-names>C.</given-names></name>; <name><surname>Rockey</surname><given-names>D. C.</given-names></name>; <name><surname>Seeff</surname><given-names>L. B.</given-names></name>; <name><surname>Serrano</surname><given-names>J.</given-names></name>; <name><surname>Stolz</surname><given-names>A.</given-names></name>; <name><surname>Tillmann</surname><given-names>H. L.</given-names></name>; <name><surname>Vuppalanchi</surname><given-names>R.</given-names></name>; <name><surname>Navarro</surname><given-names>V. J.</given-names></name>
<article-title>HLA-B*35:01 and Green Tea-Induced
Liver Injury</article-title>. <source>Hepatology</source>
<year>2021</year>, <volume>73</volume>, <fpage>2484</fpage>&#x02013;<lpage>2493</lpage>. <pub-id pub-id-type="doi">10.1002/hep.31538</pub-id>.<pub-id pub-id-type="pmid">32892374</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Mazzanti</surname><given-names>G.</given-names></name>; <name><surname>Menniti-Ippolito</surname><given-names>F.</given-names></name>; <name><surname>Moro</surname><given-names>P. A.</given-names></name>; <name><surname>Cassetti</surname><given-names>F.</given-names></name>; <name><surname>Raschetti</surname><given-names>R.</given-names></name>; <name><surname>Santuccio</surname><given-names>C.</given-names></name>; <name><surname>Mastrangelo</surname><given-names>S.</given-names></name>
<article-title>Hepatotoxicity from green tea: a
review of the literature and two unpublished cases</article-title>. <source>European Journal of Clinical Pharmacology</source>
<year>2009</year>, <volume>65</volume>, <fpage>331</fpage>&#x02013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-008-0610-7</pub-id>.<pub-id pub-id-type="pmid">19198822</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Navarro</surname><given-names>V. J.</given-names></name>; <name><surname>Bonkovsky</surname><given-names>H. L.</given-names></name>; <name><surname>Hwang</surname><given-names>S. I.</given-names></name>; <name><surname>Vega</surname><given-names>M.</given-names></name>; <name><surname>Barnhart</surname><given-names>H.</given-names></name>; <name><surname>Serrano</surname><given-names>J.</given-names></name>
<article-title>Catechins
in dietary supplements and hepatotoxicity</article-title>. <source>Dig.
Dis. Sci.</source>
<year>2013</year>, <volume>58</volume>, <fpage>2682</fpage>&#x02013;<lpage>2690</lpage>. <pub-id pub-id-type="doi">10.1007/s10620-013-2687-9</pub-id>.<pub-id pub-id-type="pmid">23625293</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Yu</surname><given-names>Z.</given-names></name>; <name><surname>Samavat</surname><given-names>H.</given-names></name>; <name><surname>Dostal</surname><given-names>A. M.</given-names></name>; <name><surname>Wang</surname><given-names>R.</given-names></name>; <name><surname>Torkelson</surname><given-names>C. J.</given-names></name>; <name><surname>Yang</surname><given-names>C. S.</given-names></name>; <name><surname>Butler</surname><given-names>L. M.</given-names></name>; <name><surname>Kensler</surname><given-names>T. W.</given-names></name>; <name><surname>Wu</surname><given-names>A. H.</given-names></name>; <name><surname>Kurzer</surname><given-names>M. S.</given-names></name>; <name><surname>Yuan</surname><given-names>J. M.</given-names></name>
<article-title>Effect of Green Tea Supplements on
Liver Enzyme Elevation: Results from a Randomized Intervention Study
in the United States</article-title>. <source>Cancer Prev Res. (Phila)</source>
<year>2017</year>, <volume>10</volume>, <fpage>571</fpage>&#x02013;<lpage>579</lpage>. <pub-id pub-id-type="doi">10.1158/1940-6207.CAPR-17-0160</pub-id>.<pub-id pub-id-type="pmid">28765194</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Oketch-Rabah</surname><given-names>H. A.</given-names></name>; <name><surname>Roe</surname><given-names>A. L.</given-names></name>; <name><surname>Rider</surname><given-names>C. V.</given-names></name>; <name><surname>Bonkovsky</surname><given-names>H. L.</given-names></name>; <name><surname>Giancaspro</surname><given-names>G. I.</given-names></name>; <name><surname>Navarro</surname><given-names>V.</given-names></name>; <name><surname>Paine</surname><given-names>M. F.</given-names></name>; <name><surname>Betz</surname><given-names>J. M.</given-names></name>; <name><surname>Marles</surname><given-names>R. J.</given-names></name>; <name><surname>Casper</surname><given-names>S.</given-names></name>; <name><surname>Gurley</surname><given-names>B.</given-names></name>; <name><surname>Jordan</surname><given-names>S. A.</given-names></name>; <name><surname>He</surname><given-names>K.</given-names></name>; <name><surname>Kapoor</surname><given-names>M. P.</given-names></name>; <name><surname>Rao</surname><given-names>T. P.</given-names></name>; <name><surname>Sherker</surname><given-names>A. H.</given-names></name>; <name><surname>Fontana</surname><given-names>R. J.</given-names></name>; <name><surname>Rossi</surname><given-names>S.</given-names></name>; <name><surname>Vuppalanchi</surname><given-names>R.</given-names></name>; <name><surname>Seeff</surname><given-names>L. B.</given-names></name>; <name><surname>Stolz</surname><given-names>A.</given-names></name>; <name><surname>Ahmad</surname><given-names>J.</given-names></name>; <name><surname>Koh</surname><given-names>C.</given-names></name>; <name><surname>Serrano</surname><given-names>J.</given-names></name>; <name><surname>Low Dog</surname><given-names>T.</given-names></name>; <name><surname>Ko</surname><given-names>R.</given-names></name>
<article-title>United States Pharmacopeia
(USP) comprehensive review of the hepatotoxicity
of green tea extracts</article-title>. <source>Toxicology Reports</source>
<year>2020</year>, <volume>7</volume>, <fpage>386</fpage>&#x02013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1016/j.toxrep.2020.02.008</pub-id>.<pub-id pub-id-type="pmid">32140423</pub-id>
</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Cho</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Yeung</surname><given-names>K.</given-names></name>; <name><surname>Cao</surname><given-names>Y.</given-names></name>; <name><surname>Uetrecht</surname><given-names>J.</given-names></name>
<article-title>Liver Injury
Caused by Green Tea Extract in PD-1&#x02013;/&#x02013; Mice: An Impaired
Immune Tolerance Model for Idiosyncratic Drug-Induced Liver Injury</article-title>. <source>Chem. Res. Toxicol.</source>
<year>2021</year>, <volume>34</volume>, <fpage>849</fpage>&#x02013;<lpage>856</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.0c00485</pub-id>.<pub-id pub-id-type="pmid">33617238</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Mauri-Hellweg</surname><given-names>D.</given-names></name>; <name><surname>Bettens</surname><given-names>F.</given-names></name>; <name><surname>Mauri</surname><given-names>D.</given-names></name>; <name><surname>Brander</surname><given-names>C.</given-names></name>; <name><surname>Hunziker</surname><given-names>T.</given-names></name>; <name><surname>Pichler</surname><given-names>W. J.</given-names></name>
<article-title>Activation of drug-specific
CD4+ and CD8+ T cells in
individuals allergic to sulfonamides, phenytoin, and carbamazepine</article-title>. <source>J. Immunol</source>
<year>1995</year>, <volume>155</volume>, <fpage>462</fpage>&#x02013;<lpage>472</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.155.1.462</pub-id>.<pub-id pub-id-type="pmid">7602118</pub-id>
</mixed-citation></ref></ref-list></back></article>
